On June 20th, Hangzhou Municipality “Implementation Opinions on Promoting the Innovative Development of Biomedical Industry in Hangzhou” (hereinafter referred to as “Opinions”) was officially implemented. It is planned to build a leading biopharmaceutical R&D and industrialization highland in 2022. The main business income will reach 100 billion yuan, and Hangzhou will become a bio-innovative city with global influence.
In recent years, Pfizer, Merck, Geria, and Lilly... The top ten pharmaceutical giants in the world have settled in Hangzhou Pharmaceutical Port; Huadong Medicine, Beida Pharmaceutical, Minsheng Pharmaceutical, Dean Diagnostics... Hangzhou Local The growing pharmaceutical companies continue to grow and develop. Hangzhou biomedical industry has maintained double-digit growth in recent years and is becoming an important growth pole for the development of emerging industries.
Improve the bio-pharmaceutical industry chain system
Development of four key areas
Hangzhou will lead the creation of a full-chain innovation platform such as the bio-pharmaceutical industry innovation R&D center, production (manufacturing) center, outsourcing and service center, attracting a group of world-class R&D, production, management and sales teams, and implementing a group of representatives to represent the future. A major project in the development direction of the bio-pharmaceutical industry, cultivating a number of leading backbone enterprises and improving the bio-pharmaceutical industry chain system.
In order to achieve the above objectives, the "Opinions" pointed out that it is necessary to develop four key areas.
1. Give priority to the development of biopharmaceuticals to give full play to the first-mover advantage in the biopharmaceutical field, and vigorously develop new biotechnology drugs such as antibody drugs, recombinant protein drugs, and new vaccines, accelerate research on immune cell therapy, stem cell and gene therapy, and break through microbial metabolism. A number of key biotechnologies such as regulation and fermentation optimization have enabled the rapid development of the biopharmaceutical industry.
2. Enhance the development of medical devices to give full play to the advantages of medical device segmentation such as biomimetic medicine, genetic diagnosis, surgical instruments, diagnostic reagents, etc., and vigorously develop high-performance medical equipment and reagents, high value-added implant materials and intelligent surgical treatment. Rehabilitation and first aid equipment continue to enhance the comprehensive strength of the city's medical device manufacturing.
3. Innovative development of chemical and pharmaceutical companies to make full use of the existing chemical and pharmaceutical development base, focusing on the prevention and treatment of major diseases such as malignant tumors, neurodegenerative diseases, cardiovascular and cerebrovascular diseases, metabolic diseases, autoimmune diseases, etc., vigorously develop new mechanisms and new High-end preparations and new excipients for targets and new indications, and strive to achieve new breakthroughs in the research and development and industrialization of chemical pharmaceutical innovation.
4. Inheriting the development of Chinese medicine industry to give full play to the unique advantages of traditional Chinese medicine brands, constantly excavating classics, and increasing the research and development of new Chinese medicines based on unilateral, prescription and hospital preparations, and the secondary development of famous Chinese patent medicines to speed up Chinese medicine. Industrial modernization process.
Biomedical industry layout
One nuclear, three gardens and more
According to the "Opinions", Hangzhou will build a high-end biomedical industry base around "one core, three parks and more points".
"One core." Taking Hangzhou Economic Development Zone as the core, we will build a bio-pharmaceutical high-end product research and development cluster with the most complete elements, the most complete links and the fastest development speed. On May 21, Hangzhou Economic Development Zone was also officially awarded the title of “Hangzhou Medical Port” by the municipal government.
"Three Parks." That is, Yuhang District Biomedical High-tech Industrial Park, High-tech Development Zone (Binjiang) Life and Health Industrial Park, and Dajiangdong Industrial Cluster Industrialization Base.
"More". That is to speed up the construction of high-tech zone (Binjiang) smart medical town (Binjiang District), China Smart Health Valley (Xiaoshan District), Xianghu Smart Health Town (Xiaoshan District), Liangzhu International Life Science Town (Yuhang District), Fuchun Medicine Valley Town (Fuyang District), Lin'an Tianmu Pharmaceutical Port (Lin'an District), Fuchun Mountain Health City (Tonglu County), China Minimally Invasive Surgery Equipment Town (Tonglu County), Wenchang Health Food Town (Zhong'an County) A number of biomedical industry characteristic bases such as Jiande High-tech Industrial Park (Jiande City).
Strengthen financial and financial support
New drug research and development can receive up to 10 million yuan reward
The bio-pharmaceutical industry has a large investment in the early stage and a long return period. Strengthening financial and financial support is an important part of industrial policy. Hangzhou has strengthened financial and financial support for the biomedical industry in various aspects.
Focus on supporting the construction of the public service platform for the industry chain. Support the construction of important public service platforms such as drug non-clinical safety evaluation institutions (GLP), drugs (including medical devices) clinical trial institutions (GCP), clinical research hospitals with special professional requirements, biomedical industry pilot platforms, data centers, etc. Give each platform a total investment of 30% and a maximum of 10 million yuan.
R&D service organizations such as local GLP, GCP, biomedical research and development outsourcing (CRO), and biomedical industry pilot platform provide services for Hangzhou biomedical enterprises that have no investment relationship, and give 5% of the actual amount of the annual contract. Up to a maximum of 5 million yuan per year.
Encourage enterprises to carry out the evaluation of the consistency of quality and efficacy of generic drugs. For drugs that pass the national consistency evaluation (different specifications are considered as one variety), each variety will be given a one-time reward of 1 million yuan; among them, the clinical effectiveness test will be given a one-time reward of 2 million yuan for each variety.
The new drug research and development of the enterprise has entered the clinical phase II and phase III research projects, and respectively awarded 1 million yuan and 2 million yuan. If the national new drug registration certificate is obtained and industrialized in this city, each type of new drug will be rewarded with 10 million yuan, and each of the second and third class new drugs will be rewarded with 5 million yuan. Through the US FDA preparation certification and industrialization in Hangzhou, each variety will be awarded 1 million yuan.
For the first time, the national medical device registration certificate was obtained and industrialized in Hangzhou. The innovative second-class medical devices were rewarded with 500,000 yuan for each product, and each of the three types of medical devices was rewarded with 800,000 yuan.
In the Hangzhou medical institutions to purchase the first (set) of medical equipment identified by the provincial and municipal departments, 50% of the purchase amount of a single equipment, a total of up to 2 million yuan for a single medical institution.
In addition, special major projects, with the consent of the Hangzhou Municipal Government, can be given policy support in the form of “one case, one discussion”. (Article source: Investment in Hangzhou)